Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
The ongoing outbreak of highly pathogenic avian influenza virus (HPAIV) in birds, the incidence of transmission to humans with a resulting high mortality rate, and the possibility of a human pandemic warrant the development of effective human vaccines against HPAIV. We developed an experimental live-attenuated vaccine for direct inoculation of the respiratory tract based on recombinant avian Newcastle disease virus (NDV) expressing the hemagglutinin (HA) glycoprotein of H5N1 HPAIV (NDV-HA). Expression of the HPAIV HA gene slightly reduced NDV virulence, as evidenced by the increased mean embryo death time and reduced replication in chickens. NDV-HA was administered to African green monkeys in two doses of 2 x 10(7) infectious units each with a 28-day interval to evaluate the systemic and local antibody responses specific to H5N1 HPAIV. The virus was shed only at low titers from the monkeys, indicative of safety. Two doses of NDV-HA induced a high titer of H5N1 HPAIV-neutralizing serum antibodies in all of the immunized monkeys. Moreover, a substantial mucosal immunoglobulin A response was induced in the respiratory tract after one and two doses. The titers of neutralizing antibodies achieved in this study suggest that the vaccine would be likely to prevent mortality and reduce morbidity caused by the H5N1 HPAIV. In addition, induction of a local immune response in the respiratory tract is an important advantage that is likely to reduce or prevent transmission of the virus during an outbreak or a pandemic. This vaccine is a candidate for clinical evaluation in humans.
DiNapoli
Joshua M
JM
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases/NIH, 50 South Drive, Bethesda, MD 20892, USA.
Yang
Lijuan
L
Suguitan
Amorsolo
A
Elankumaran
Subbiah
S
Dorward
David W
DW
Murphy
Brian R
BR
Samal
Siba K
SK
Collins
Peter L
PL
Bukreyev
Alexander
A
D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D001483:Base Sequence; D002645:Chickens; D002522:Chlorocebus aethiops; D005822:Genetic Vectors; D006801:Humans; D007070:Immunoglobulin A / Q000737:chemistry; D005585:Influenza in Birds / Q000517:prevention & control; D008969:Molecular Sequence Data; D009522:Newcastle disease virus / Q000235:genetics*; D009975:Orthomyxoviridae / Q000235:genetics*; D012367:RNA, Viral / Q000378:metabolism; D012137:Respiratory System / Q000821:virology*; D014765:Viral Vaccines / Q000737:chemistry
D000906:Antibodies; D007070:Immunoglobulin A; D012367:RNA, Viral; D014765:Viral Vaccines
J Hyg (Lond). 1972 Dec;70(4):767-77
4509641
J Virol. 2004 Sep;78(18):10054-63
15331738
J Clin Microbiol. 1986 Jul;24(1):47-51
3722365
J Virol. 1995 Sep;69(9):5677-86
7637014
J Virol. 1998 Feb;72(2):891-9
9444980
Vaccine. 1999 Mar 17;17(11-12):1355-8
10195770
J Virol. 1999 Jul;73(7):5903-11
10364342
Virology. 2004 Dec 5;330(1):8-15
15527829
J Virol. 2005 Feb;79(4):2191-8
15681421
J Infect Dis. 2005 Apr 1;191(7):1093-104
15747245
J Infect Dis. 2005 Apr 15;191(8):1210-5
15776364
J Virol. 2005 Nov;79(21):13275-84
16227250
Emerg Infect Dis. 2006 Jan;12(1):66-72
16494720
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8203-8
16717196
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8197-202
16717197
J Infect Dis. 2006 Oct 15;194(8):1040-3
16991078
J Virol. 2007 Jan;81(1):150-8
17050610
J Virol. 2007 Jun;81(12):6379-88
17428868
Eur J Immunol. 1984 Apr;14(4):350-6
6609824
J Virol. 2000 Aug;74(15):6821-31
10888621
Virology. 2000 Dec 5;278(1):168-82
11112492
Lancet. 2001 Jun 16;357(9272):1937-43
11425416
Pediatr Infect Dis J. 2003 May;22(5):394-405
12792378
Microb Pathog. 2004 Jan;36(1):1-10
14643634
Lancet. 2003 Dec 13;362(9400):1959-66
14683655
Lancet. 2004 Jun 26;363(9427):2122-7
15220033